UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	0.5							

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person * HEPPELL JAMES L					2. Issuer Name and Ticker or Trading Symbol Emerald Bioscience, Inc. [EMBI]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner					
(Last) (First) (Middle) 5910 PACIFIC CENTER BLVD, SUITE 320					3. Date of Earliest Transaction (Month/Day/Year) 08/07-05:00/2020								-	Officer (give t	itle below)	Other	(specify below	v)	
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing/Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SAN DIEGO, CA 92121 (City) (State) (Zip)					Table I - Non-Derivative Securities Acqui							Securi	ties Acquir						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			Execution Date, if any			(Instr. 8)		or Disposed of (D))	5. Amount of Securities Beneficia Owned Following Reported Transaction(s)			6. Ownership Form:	Beneficial			
				(Mon	(Month/Day/Year)		Code		V	An	nount	(A) or (D)	Price	(Instr. 3 and 4)				Ownership (Instr. 4)	
Common Stock 08/07- 05:00/2020						P			500	0,000		\$ 50,000 (1)	500,000		1	D			
Reminder:	Report on a s	separate line for each	a class of securities b	II - Deri	ivati	ve Securi	ities Acc	qui	Pers this curr	sons forn ently	n are r y valid sed of,	ot rec I OMB or Ben	quired to r control n				in SEC	1474 (9-02)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if	4. Transac Code	Cransaction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			Options, convertible securion 6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			and	7. Title a	Amount of Number of Shares	8. Price of Derivative Security (Instr. 5) (Instr. 5) 9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)		Owners Form of Derivat Security Direct (or Indir	Ownershi (Instr. 4) Ovnershi		
Director Option Grant (Right to Buy)	\$ 0.045	08/07- 05:00/2020		A		1,000,0	000		(2))		/07-)/2030	Commo Stock		\$ 0	1,200,000) D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
HEPPELL JAMES L 5910 PACIFIC CENTER BLVD SUITE 320 SAN DIEGO, CA 92121	X						

Signatures

/s/James L. Heppell	08/11-05:00/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Private purchase transaction from Emerald Health Sciences at \$0.10 per share.
- (2) Each of the Options shall be exercisable for a price of \$0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.